프로스타글란딘 유사체 시장 예측(-2030년) : 제품 유형별, 투여 경로별, 유통 채널별, 용도별, 지역별 세계 분석

According to Stratistics MRC, the Global Prostaglandin Analogs Market is accounted for $3.9 billion in 2024 and is expected to reach $6.1 billion by 2030, growing at a CAGR of 7.5% during the forecast period. Synthetic substances called prostaglandin analogs replicate the actions of natural prostaglandins, which are lipid molecules involved in a number of physiological functions like inflammation and smooth muscle contraction. To reduce intraocular pressure in diseases like glaucoma, these analogs are frequently used in medical treatments, particularly in ophthalmology.

According to clinical research published in Frontiers in Pharmacology, prostaglandin analogs (PGAs) are considered the first-line treatment for glaucoma, with the most effective long-term therapy being 0.03% bimatoprost, followed by 0.005% latanoprost and 0.004% travoprost.

Market Dynamics:

Driver:

Rising prevalence of ophthalmic conditions

The increasing incidence of glaucoma, ocular hypertension, and other eye disorders is driving demand for prostaglandin analogs. As the global population ages, the prevalence of these conditions is growing, necessitating effective treatments. Prostaglandin analogs have become a first-line therapy for many ophthalmic issues due to their efficacy in lowering intraocular pressure. The rising disease burden is compelling more patients to seek treatment, fueling market growth.

Restraint:

High costs

The high costs associated with branded prostaglandin analog medications can limit patient access and market growth, especially in developing regions. Patent protection allows manufacturers to charge premium prices for these drugs. The expenses of research, development, clinical trials, and regulatory approvals are reflected in the final product costs. For many patients, the long-term use of these medications represents a significant financial burden. This cost barrier may lead some to opt for alternative, less expensive treatments.

Opportunity:

Expansion into new therapeutic areas

There is potential to expand the use of prostaglandin analogs beyond glaucoma and ocular hypertension into other therapeutic areas. Ongoing research is exploring their efficacy for conditions like dry eye disease, retinal disorders, and corneal healing. The anti-inflammatory and neuroprotective properties of these drugs make them promising candidates for various ophthalmic applications. Successful development of new indications would significantly expand the market and provide additional revenue streams for manufacturers.

Threat:

Regulatory challenges

Stringent regulatory requirements for ophthalmic medications pose a threat to market growth. Obtaining and maintaining regulatory approvals for prostaglandin analogs can be a lengthy and costly process. Changing regulations, safety concerns, or adverse events could lead to market withdrawals or restrictions. Post-marketing surveillance and pharmacovigilance requirements add to operational costs. Navigating the complex regulatory landscape across different regions presents ongoing challenges for manufacturers in this market.

Covid-19 Impact:

The COVID-19 pandemic disrupted the prostaglandin analogs market in several ways. Lockdowns and safety measures led to reduced patient visits for routine eye care, potentially delaying diagnoses and treatment initiations. Supply chain disruptions affected manufacturing and distribution. However, the pandemic also accelerated the adoption of telemedicine for ophthalmic care, potentially improving long-term access to prescriptions and follow-ups. As healthcare systems recover, pent-up demand for eye care services may drive market growth.

The topical segment is expected to be the largest during the forecast period

The topical segment is predicted to secure the largest market share throughout the forecast period. Topical administration, primarily through eye drops, is the dominant route for prostaglandin analogs. This method offers several advantages, including direct delivery to the target site, minimal systemic absorption, and ease of use for patients. Topical formulations allow for precise dosing and reduced side effects compared to systemic treatments. The convenience of once-daily application for many prostaglandin analog eye drops improves patient compliance. Ongoing innovations in topical drug delivery systems, such as preservative-free formulations and sustained-release technologies, are further driving the growth of this segment.

The ocular hypertension segment is expected to have the highest CAGR during the forecast period

The ocular hypertension segment is projected to witness substantial growth during the projection period. Ocular hypertension, characterized by elevated intraocular pressure without optic nerve damage or visual field loss, represents a significant market opportunity. Early intervention with prostaglandin analogs can effectively manage intraocular pressure and potentially prevent progression to glaucoma. The growing awareness of ocular hypertension as a risk factor for glaucoma is leading to increased screening and treatment initiation. As diagnostic technologies improve, more cases are being identified at earlier stages. The preventive approach to managing ocular hypertension is expected to drive rapid growth in this segment.

Region with largest share:

The North America region is projected to account for the largest market share during the forecast period. The region has a high prevalence of glaucoma and ocular hypertension, coupled with an aging population. Advanced healthcare infrastructure and high healthcare spending enable greater access to these medications. Strong presence of key market players and ongoing research activities contribute to market leadership. Additionally, favorable reimbursement policies and insurance coverage for glaucoma treatments support market growth.

Region with highest CAGR:

The Asia Pacific region is projected to achieve the highest CAGR during the forecast period. Factors driving this include a large and aging population, increasing prevalence of eye disorders, and improving healthcare access. Rising disposable incomes and an expanding middle class in countries like China and India are enabling greater affordability of advanced treatments. Government initiatives to combat blindness and improve eye care are creating a favorable market environment. Growing awareness of eye health and expanding healthcare infrastructure are also contributing to market expansion in this region.

Key players in the market

Some of the key players in Prostaglandin Analogs Market include Pfizer Inc., Allergan plc, Novartis AG, Bayer AG, GlaxoSmithKline plc, Merck & Co., Inc., Santen Pharmaceutical Co., Ltd., Ocular Therapeutix, Inc., Aerie Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Yonsung Fine Chemicals, Everlight Chemical, Piramal Enterprises, Bio-Techne Corporation, Mironova Labs, Chirogate, Cepia, LLC, and Johnson Matthey.

Key Developments:

In October 2024, GSK plc and Chimagen Biosciences (Chimagen), a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE), from Chimagen for $300 million upfront. GSK plans to develop and commercialise CMG1A46 with a focus on B cell-driven autoimmune diseases, such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), with potential to expand into related autoimmune diseases.

In September 2024, Novartis announced that the US Food and Drug Administration (FDA) has approved Kisqali(R) (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer (EBC) at high risk of recurrence, including those with node-negative (N0) disease.

In November 2023, Santen received European Commission approval for Catiolanze(R), a cationic emulsion of latanoprost 50μg/mL. This preservative-free prostaglandin analog is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The approval follows positive results from a Phase III clinical trial that demonstrated non-inferiority to traditional latanoprost solutions and improved outcomes for patients with Ocular Surface Disease (OSD).

Product Types Covered:

• Latanoprost
• Bimatoprost
• Travoprost
• Tafluprost
• Other Product Types

Route of Administrations Covered:

• Topical
• Oral
• Injectable

Distribution Channels Covered:

• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies
• Online Distribution

Applications Covered:

• Glaucoma Treatment
• Lash Growth Enhancement
• Ocular Hypertension
• Dry Eye Disease
• Gastric Protection
• Other Applications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Prostaglandin Analogs Market, By Product Type

• 5.1 Introduction
• 5.2 Latanoprost
• 5.3 Bimatoprost
• 5.4 Travoprost
• 5.5 Tafluprost
• 5.6 Other Product Types

6 Global Prostaglandin Analogs Market, By Route of Administration

• 6.1 Introduction
• 6.2 Topical
• 6.3 Oral
• 6.4 Injectable

7 Global Prostaglandin Analogs Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Hospital Pharmacies
• 7.3 Retail Pharmacies
• 7.4 Specialty Pharmacies
• 7.5 Online Distribution

8 Global Prostaglandin Analogs Market, By Application

• 8.1 Introduction
• 8.2 Glaucoma Treatment
• 8.3 Lash Growth Enhancement
• 8.4 Ocular Hypertension
• 8.5 Dry Eye Disease
• 8.6 Gastric Protection
• 8.7 Other Applications

9 Global Prostaglandin Analogs Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Pfizer Inc.
• 11.2 Allergan plc
• 11.3 Novartis AG
• 11.4 Bayer AG
• 11.5 GlaxoSmithKline plc
• 11.6 Merck & Co., Inc.
• 11.7 Santen Pharmaceutical Co., Ltd.
• 11.8 Ocular Therapeutix, Inc.
• 11.9 Aerie Pharmaceuticals, Inc.
• 11.10 Sun Pharmaceutical Industries Ltd.
• 11.11 Yonsung Fine Chemicals
• 11.12 Everlight Chemical
• 11.13 Piramal Enterprises
• 11.14 Bio-Techne Corporation
• 11.15 Mironova Labs
• 11.16 Chirogate
• 11.17 Cepia, LLC
• 11.18 Johnson Matthey